Zydus Cadila agrees sub-licensing deal with MPP

Healthcare provider Zydus Cadila has signed a sub-licensing agreement with the Medicines Patent Pool (MPP) centring on the generic production of Daklinza (daclatasvir).

Zydus revealed the non-exclusive, royalty-free agreement with yesterday, July 7.

Daklinza, produced by pharmaceutical company Bristol-Myers Squibb (BMS), is an antiviral drug used to help cure hepatitis C.

The agreement allows Zydus to produce and sell its generic in 112 low and middle-income countries.

According to Zydus, between 130 and 150 million people are estimated to suffer from hepatitis C.

Pankaj Patel, chairman and managing director of Zydus, said: “We are committed to delivering better therapy outcomes and improving the quality of life of people.

“We are happy to work together with the MPP and BMS to serve the cause of healthcare by providing access to new and affordable therapies.”